Zantac Makers, Retailers Urge Nix Of Medical Monitoring Class

By Carolina Bolado (August 24, 2021, 6:48 PM EDT) -- Manufacturers and retailers of the heartburn medication Zantac urged a Florida federal judge on Monday to dismiss the medical monitoring claims of a class of consumers in multidistrict litigation because they had failed to show that their exposure to the carcinogen in the drug was enough to increase their risk of cancer.

The drugmakers and retailers argued that the plaintiffs are not entitled to the costs of medical monitoring for just any exposure to N-nitrosodimethylamine, or NDMA, the carcinogen that has been found in Zantac and its generic equivalent ranitidine.

The defendants noted that when U.S. District Judge Robin Rosenberg previously...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!